Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study-Reference-Cited by-同舟云学术

Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study

Published:2023-01 Issue:1 Volume:23 Page:45-55
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Carazo Sara,Skowronski Danuta M,Brisson Marc,Barkati Sapha,Sauvageau Chantal,Brousseau Nicholas,Gilca Rodica,Fafard Judith,Talbot Denis,Ouakki Manale,Gilca Vladimir,Carignan Alex,Deceuninck Geneviève,De Wals Philippe,De Serres Gaston

Funder

Ministère de la Santé et des Services sociaux

Institut National de Santé Publique du Québec

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference24 articles.

1. Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant;Andrews;N Engl J Med,2022

2. Striking antibody evasion manifested by the omicron variant of SARS-CoV-2;Liu;Nature,2022

3. COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England;Kirsebom;Lancet Infect Dis,2022

4. Effect of mRNA vaccine boosters against SARS-CoV-2 omicron infection in Qatar;Abu-Raddad;N Engl J Med,2022

5. Occurrence and significance of omicron BA.1 infection followed by BA.2 reinfection;Stegger;medRxiv,2022

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of nirsevimab against RSV-bronchiolitis in paediatric ambulatory care: a test-negative case–control study;The Lancet Regional Health - Europe;2024-09

2. SARS-COV-2 breakthrough infection and its covariates among healthcare providers of a hospital in Bangladesh during the omicron wave;Heliyon;2024-09

3. Planning and adjusting the COVID-19 booster vaccination campaign to reduce disease burden;Infectious Disease Modelling;2024-09

4. Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection;Frontiers in Public Health;2024-08-26

5. Safety and durability of mRNA-1273–induced SARS-CoV-2 immune responses in adolescents: results from the phase 2/3 TeenCOVE trial;eClinicalMedicine;2024-08